Emily Bury: From Emerging Evidence to Better Patient Care at ISTH 2026
Emily Bury, Advanced Nurse Practitioner for Thrombosis at St.Vincent’s Healthcare Group, shared a post on LinkedIn:
“A fantastic few days at ISTH 2026 in Paris, with rich learning, inspiring discussions and valuable opportunities to connect with colleagues from around the world.
It was exciting to see women’s health take centre stage, including the launch of the ‘Women’s Health Hub‘—a significant step towards advancing research, education and equitable care for women with thrombosis and bleeding disorders.
Another key highlight was the continued focus on ‘cancer-associated VTE‘, with the ‘API-CAT trial‘ demonstrating that extended treatment with ‘reduced-dose apixaban’ was non-inferior to the full treatment dose for preventing recurrent VTE, while reducing clinically relevant bleeding.
Delighted to attend alongside Tracy Egan of the Irish Heart Foundation – (supporting Thrombosis patients).
Looking forward to bringing insights from ISTH back to support better patient care.”
Stay updated with Hemostasis Today.
-
Aug 14, 2026, 23:18Claire Hills: New Paper on Immune Surveillance and Immune Evasion of Senescent Cells
-
Aug 14, 2026, 23:16Are We Overlooking What Matters Most to Women with Von Willebrand Disease? – RPTH Journal
-
Aug 14, 2026, 23:15Markus Müller: A New Base Editing Approach Targeting PCSK9 to Lower Cholesterol Levels
-
Aug 14, 2026, 23:14Chokri Ben Lamine: Avatrombopag in Hematology – Dosing and Monitoring
-
Aug 14, 2026, 23:13Bianca Rocca: PRECISE-DAPT Score Identifies Bleeding Risk After CABG in Patients With POAF
-
Aug 14, 2026, 19:04Ravi Kumar: Why Lupus Anticoagulant Predicts Clots, Not Bleeding
-
Aug 14, 2026, 18:53Veli Bakalov: The Number Every Hematologist Should Know in Polycythemia Vera
-
Aug 14, 2026, 18:41Marta Velia Antonini: Can Nitric Oxide Protect the ECMO Circuit Without Systemic Anticoagulation?
-
Aug 14, 2026, 18:30Irina Gontschar: What the Epkinly FDA Review Teaches Us About Sponsor Oversight